Rosetta Genomics Ltd. engages in the provision of therapeutic, diagnostic product development, and medical research services. The firm is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY, and RosettaGX Reveal. The firm's therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. The firm focuses on developing a diagnostic assay, RosettaGX Reveal V2. The company is also focusing on developing Bladder cancer risk stratification.
